CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021
June 09 2021 - 4:30PM
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, today announced that it will issue its
financial results for the quarter ended March 31, 2021, on
Wednesday, June 16, 2021.
The Company will be hosting a Virtual Investor Event on Tuesday,
June 22, 2021, at 9:00 a.m. - 11:00 a.m. EDT / 3:00 p.m. - 5:00
p.m. CEST and will not be hosting a separate quarterly earnings
call. To register and learn more about CENTOGENE’s Virtual Investor
Event, visit: https://www.centogene.com/virtual-investor-event
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository with
over 3.9 billion weighted data points from approximately 600,000
patients representing over 120 different countries as of December
31, 2020.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Important Notice and Disclaimer
This press release contains statements that constitute
“forward-looking statements” as that term is defined in the United
States Private Securities Litigation Reform Act of 1995, including
statements that express the Company’s opinions, expectations,
beliefs, plans, objectives, assumptions, or projections regarding
future events or future results, in contrast with statements that
reflect historical facts. Examples include discussion of our
strategies, financing plans, growth opportunities, and market
growth. In some cases, you can identify such forward-looking
statements by terminology such as “anticipate,” “intend,”
“believe,” “estimate,” “plan,” “seek,” “project” or “expect,”
“may,” “will,” “would,” “could,” or “should,” the negative of these
terms or similar expressions. Forward-looking statements are based
on management’s current beliefs and assumptions and on information
currently available to the Company. However, these forward- looking
statements are not a guarantee of our performance, and you should
not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties, and other
variable circumstances, such as negative worldwide economic
conditions and ongoing instability and volatility in the worldwide
financial markets, the effects of the COVID-19 pandemic on our
business and results of operations, possible changes in current and
proposed legislation, regulations and governmental policies,
pressures from increasing competition and consolidation in our
industry, the expense and uncertainty of regulatory approval,
including from the U.S. Food and Drug Administration, our reliance
on third parties and collaboration partners, including our ability
to manage growth and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, or other
factors. Such risks and uncertainties may cause the statements to
be inaccurate and readers are cautioned not to place undue reliance
on such statements. Many of these risks are outside of the
Company’s control and could cause its actual results to differ
materially from those it thought would occur. The forward-looking
statements included in this press release are made only as of the
date hereof. The Company does not undertake, and specifically
declines, any obligation to update any such statements or to
publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as
required by law.
For further information, please refer to the Risk Factors
section in our Annual Report for the year ended December 31, 2020,
on Form 20-F filed with the SEC on April 15, 2021, and other
reports and documents furnished to or filed with the U.S.
Securities and Exchange Commission (SEC). You may get these
documents by visiting EDGAR on the SEC website
at www.sec.gov.
Media Contact:
CENTOGENE
Lennart Streibel
Investor Relations
Investor.relations@centogene.com
FTI Consulting
Bridie Lawlor O’Boyle
+1.917.929.5684
bridie.lawlor@fticonsulting.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Oct 2023 to Oct 2024